Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
3.94M | 4.95M | 4.19M | 2.15M | 0.00 | Gross Profit |
2.90M | 2.87M | 2.65M | 1.20M | 0.00 | EBIT |
-3.35M | -979.92K | 648.35K | 10.64K | -15.64K | EBITDA |
-2.79M | -1.63M | 1.01M | 37.05K | 0.00 | Net Income Common Stockholders |
-3.32M | -1.01M | 584.39K | 10.64K | -15.64K |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
6.20M | 12.18M | 615.75K | 326.71K | 0.00 | Total Assets |
15.12M | 19.69M | 6.86M | 7.48M | 495.15K | Total Debt |
597.14K | 832.07K | 1.09M | 1.35M | 0.00 | Net Debt |
-5.60M | -11.35M | 470.97K | 1.02M | 0.00 | Total Liabilities |
1.19M | 2.20M | 1.30M | 2.20M | 5.28K | Stockholders Equity |
13.93M | 17.49M | 5.56M | 5.29M | 489.87K |
Cash Flow | Free Cash Flow | |||
-5.96M | -782.63K | 1.15M | -5.58M | -505.51K | Operating Cash Flow |
-5.47M | -736.97K | 1.38M | -1.33M | -505.51K | Investing Cash Flow |
-484.86K | -45.66K | -229.47K | -4.26M | 0.00 | Financing Cash Flow |
-25.24K | 12.35M | -856.79K | 5.91M | 505.51K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | $4.73B | 24.96 | 7.93% | 1.25% | -0.99% | ― | |
63 Neutral | $4.21B | 11.55 | 5.28% | 250.72% | 4.13% | -9.42% | |
55 Neutral | $4.26B | ― | -48.63% | ― | -1.72% | -94.98% | |
51 Neutral | $10.72B | ― | 0.88% | ― | 14.61% | 85.44% | |
51 Neutral | $2.64B | ― | -8.18% | ― | -24.10% | -189.99% | |
50 Neutral | $41.99M | ― | -30.59% | ― | -44.07% | -78.93% | |
47 Neutral | $63.84M | ― | -5.86% | ― | 31.09% | 35.51% |
Laser Photonics Corporation has acquired Control Micro Systems to expand its market reach into the pharmaceutical industry, leveraging CMS’s precision laser solutions for controlled-release medications. This strategic move allows Laser Photonics to diversify into a recession-resistant sector, enhance its technological capabilities, and capitalize on growing demand for laser-based drug delivery and packaging compliance solutions. The acquisition also promises a seamless transition for CMS’s workforce and continued service for existing customers.